{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:16:21Z","timestamp":1782227781225,"version":"3.54.5"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T00:00:00Z","timestamp":1435881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>According to the 2008 World Health Organization (WHO) Classification of Tumors of the Haematopoietic and Lymphoid Tissues, the finding of B lymphoblasts in the blood or bone marrow of a patient with chronic myelogenous leukemia, <jats:italic>BCR\u2010ABL1<\/jats:italic>+ (CML) should raise a concern for progression of the disease to B\u2010lymphoblastic blast phase. Data addressing the incidence and phenotypic features of abnormal B lymphoblasts in CML, and whether the detection of B lymphoblasts inexorably heralds blast phase in CML, though, are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed a consecutive series of patients with newly diagnosed CML who had undergone bone marrow examination with flow cytometric immunophenotyping. Polychromatic immunophenotyping data were reviewed, and clinical follow\u2010up data were obtained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A precursor B\u2010cell population with an abnormal composite immunophenotype was detected in 4 of 36 (11.1%) diagnostic bone marrow samples, at levels ranging from 0.01% to 0.30% of viable single cells acquired. The most common phenotypic aberrations were abnormally bright expression of CD10 and CD19 (seen in four and three cases, respectively), and abnormally dim expression of CD38 (seen in four cases). All three patients with adequate clinical follow\u2010up have achieved and maintained a deep or major molecular response with a tyrosine kinase inhibitor, and none has progressed to B\u2010lymphoblastic blast phase (follow\u2010up duration: 17\u201346 months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In chronic\u2010phase CML, a small (&lt;0.5%) abnormal B\u2010lymphoblast population is present in a significant minority of diagnostic bone marrow samples, but does not inevitably herald progression to B\u2010lymphoblastic blast phase. \u00a9 2015 International Clinical Cytometry Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.21250","type":"journal-article","created":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T02:24:25Z","timestamp":1430187865000},"page":"275-278","source":"Crossref","is-referenced-by-count":13,"title":["Detection of small abnormal <scp>B<\/scp>\u2010Lymphoblast populations at diagnosis of chronic myelogenous leukemia, <scp><i>BCR<\/i><\/scp>\u2010<scp><i>ABL<\/i><\/scp><i>1+<\/i>: Incidence, phenotypic features, and clinical implications"],"prefix":"10.1002","volume":"92","author":[{"given":"Elena","family":"Vrotsos","sequence":"first","affiliation":[{"name":"Department of Pathology &amp; Laboratory Medicine Hartford Hospital Hartford Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gorgan","sequence":"additional","affiliation":[{"name":"Department of Pathology &amp; Laboratory Medicine Hartford Hospital Hartford Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2063-8832","authenticated-orcid":false,"given":"Joseph A.","family":"DiGiuseppe","sequence":"additional","affiliation":[{"name":"Department of Pathology &amp; Laboratory Medicine Hartford Hospital Hartford Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,3]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"32","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Vardiman JW","year":"2008"},{"key":"e_1_2_6_3_1","first-page":"1211","article-title":"The immunophenotype of blast transformation of chronic myelogenous leukemia: A high frequency of mixed lineage phenotype in \u201clymphoid\u201d blasts and a comparison of morphologic, immunophenotypic, and molecular findings","volume":"11","author":"Khalidi HS","year":"1998","journal-title":"Mod Pathol"},{"key":"e_1_2_6_4_1","first-page":"168","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Borowitz MJ","year":"2008"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21101"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-357-2_8"},{"key":"e_1_2_6_7_1","volume-title":"Manual of Molecular and Clinical Laboratory Immunology","author":"DiGiuseppe JA."},{"key":"e_1_2_6_8_1","first-page":"1367.","article-title":"Detection of phenotypically abnormal B\u2010lymphoblast populations in chronic\u2010phase chronic myelogenous leukemia, BCR\u2010ABL1+ by polychromatic flow cytometry: A report of two cases","volume":"137","author":"Gorgan M","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_6_9_1","first-page":"700.","article-title":"Abnormal B lymphoid blasts may not always indicate accelerated or blast phase in chronic myelogenous leukemia (CML)","volume":"142","author":"Soma L","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20440"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20584"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.5858\/2006-130-680-CACFCI"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20363"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2498"},{"key":"e_1_2_6_15_1","first-page":"176","article-title":"Update on current monitoring recommendations in chronic myeloid leukemia: Practical points for clinical practice","volume":"2013","author":"Oehler V","year":"2013","journal-title":"ASH Educ Program Book"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijh.13.57"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324004"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.b.21250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.b.21250","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.21250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T22:23:16Z","timestamp":1696544596000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.21250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,3]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/cyto.b.21250"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.21250","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,3]]}}}